HYFTOR 0.2% gel (sirolimus) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		_ MEMBER'S FIRST NA	MEMBER'S FIRST NAME:	
important for the review (e			y additional documentation that is request). Information contained in	
MEMBER INFORMATION			URGENT	
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:	DATE OF BIRTH:	
STREET ADDRESS:				
CITY:		STATE: ZIP	CODE:	
PATIENT INSURANCE ID N	NUMBER:			
FOLLOWING LINK: PRIMETHERAPEUTICS. PATIENT'S AUTHORIZED R		LE):		
PRESCRIBER INFORMATION	ON			
LAST NAME:		FIRST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:	
STREET ADDRESS:				
CITY:		STATE: ZIP	STATE: ZIP CODE:	
REQUESTOR (if different than prescriber):		OFFICE CONTACT PER	OFFICE CONTACT PERSON:	
MEDICATION OR MEDICA	AL DISPENSING INFORMATION	N		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
NEW THERAPY DURATION OF THERAPY (RENEWAL SPECIFIC DATES):	IF RENEWAL: DATE THE	HERAPY INITIATED:	

Continued on next page.



HYFTOR 0.2% gel (sirolimus) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:		NAME:
1. HAS THE PATIENT TRIED ANY OTHE	ER MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
☐ Facial Angiofibroma associated with Tub		
□ Other Diagnosis ICD-10 (
PRIOR AUTHORIZATION.	N: PLEASE PROVIDE ALL RELEVANT CLINIC	CALINFORMATION TO SUPPORT A
Is the patient using this drug as part of	of a clinical trial? □ Ves □ No	
is the patient using this drug as part	n a cliffical criai: 1 res 1 reo	
Does the patient have 3 or more redo	dish papules of facial angiofibroma's? (d	ocumentation required with number
and size) □ Yes □ No	, help and a second	
Renewal Criteria, answer the following	ng:	
Has the patient had at least a 50% rea	duction in size and 2-level reduction in r	edness? Yes No *Please submit
documentation.		
Are there any other comments, diagr	noses, symptoms, medications tried or fa	ailed, and/or any other information the
physician feels is important to this re	view?	
	re covered on all plans. This request may	be denied unless all required
information is received.		
	on provided is true and accurate to the be	•
1	up or its designees may perform a routine	•
information necessary to verify the ac	curacy of the information reported on th	iis form.
Prescriber Signature or Electronic I.D.	. Verification:	Date:
3		
	companying this transmission contain confidentia	
	reby notified that any disclosure, copying, distribu u have received this information in error, please n	
and arrange for the return or destruction of th		ionly the sender infinediately (via return FAX)

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

Prime THERAPEUTICS*